Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Mererid Evans et al.|The Lancet|2018Cited by 1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyDavid G. Pfister, Susan Darlow, Sharon Spencer et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trialRobert I. Haddad, Marshall R. Posner, Anne O’Neill et al.|The Lancet Oncology|2013Cited by 748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018A. Dimitrios Colevas, Susan Darlow, Sue S. Yom et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 632
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022Jimmy J. Caudell, Susan Darlow, Maura L. Gillison et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 532